reports
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare C...
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ET NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025. The fireside chat is scheduled to take place on Tuesday, December 2, 2025, at 12:30 PM ET. A live webcast of the fireside chat will be available on the Eve...
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of Ameri...
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 27 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. The Company’s growth between fiscal years 2021 to 2024 was fueled by BRIUMVI® revenues, which was approved in the United States by the Food and Drug Administration (FDA) t...
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammati...
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit Fireside chat scheduled for Wednesday November 12, 2025 at 10:00 AM ET NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12 – 13, 2025. The fireside chat is scheduled to take place on Wednesday, November 12, 2025, at 10:00 AM ET. A live webcast of the fireside chat will be ava...
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raise...
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target to approximately $585 million Conference call to be held today, Monday, November 3, 2025, at 8:30 AM ET NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third qu...
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financia...
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-4...
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Eval...
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and Day 15 dosing schedule for IV BRIUMVI® (ublituximab-xiiy), the company’s novel, glycoengineered, anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS). The primary endpoint of this trial is non inferior exposure with ...
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Mul...
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 6 years of continuous treatment, with no new safety signals emerging with prolonged treatment NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated d...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 24 - 26, 2025 in Barcelona, Spain. ...
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollme...
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimens NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the company’s anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS). BRIUMVI is currently approved in the United States, as well as several ex-US territories, as a one-hour intravenous (IV) infusion administered twice...
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Glob...
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, being held in New York, NY on September 8 – 10, 2025. The fireside chat is scheduled to take place on Monday, September 8, 2025, at 10:30am ET. A live webcast of the fires...
TG Therapeutics Announces Completion of Existing Share Repurchase Prog...
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under that program, the Company repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share. In addition, the Company’s Board of Directors has authorized a new share repurchase program to...
TG Therapeutics to Participate in the Cantor Global Healthcare Confere...
TG Therapeutics to Participate in the Cantor Global Healthcare Conference Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held in New York, NY on September 3 - 5, 2025. The fireside chat is scheduled to take place on Wednesday, September 3, 2025, at 10:20am ET. A live webcast of the fireside chat will be available on the Even...
TG Therapeutics Reports Second Quarter 2025 Financial Results and Rais...
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Conference call to be held today, Monday, August 4, 2025, at 8:30 AM ET NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2025, along with recent company developments...
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financi...
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update Conference Call to be Held Monday, August 4, 2025, at 8:30 am ET NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the second quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407...
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global...
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET. NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025. The fireside chat is scheduled to take place on Tuesday, June 10, 2025, at 10:40am ET. A live webcast of the fireside chat will be avail...
TG Therapeutics to Participate in the Jefferies Global Healthcare Conf...
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference Fireside chat scheduled for Wednesday, June 4, 2025, at 12:50pm ET NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 3-5, 2025. The fireside chat is scheduled to take place on Wednesday, June 4, 2025, at 12:50 PM ET. A live webcast of the fireside chat will be availab...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple S...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Links to each presentation are included below. “We were pleased to present three encore presentations yesterday during the CM...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 28-31, 2025 in Phoenix, Arizona. Abstracts are now available online and can be accessed on the CMSC ...
TG Therapeutics Reports First Quarter 2025 Financial Results and Raise...
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along w...
TG Therapeutics to Host Conference Call on First Quarter 2025 Financia...
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update Conference call to be held Monday, May 5, 2025, at 8:30 AM ET NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.